In October 2007, the FDA introduced the labeling for all PDE5 inhibitors, together with tadalafil, requires a additional notable warning with the possible chance of sudden hearing reduction as the results of publish-internet marketing reviews of non permanent deafness affiliated with use of PDE5 inhibitors.[19]The dose could be increased to 20 mg